Effects of intravascular volume therapy using hydroxyethyl starch (130/0.4) on post‐operative bleeding and transfusion requirements in children undergoing cardiac surgery: a randomized clinical trial
Authors:
- 15 November 2005
- journal article
- research article
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 50 (1) , 108-111
Abstract
Background: Hydroxyethyl starch (HES) used for intravascular volume expansion may cause coagulation abnormalities, especially in cardiac patients. Although low molecular weight HES (130/0.4) has been developed to minimize its influence on coagulation, experience with HES (130/0.4) in children is limited. Therefore, we evaluated the effects of a HES (130/0.4) infusion on post‐operative blood loss in children undergoing cardiac surgery.Methods: Forty‐two children undergoing cardiac surgery were assigned at random to receive either 10 ml/kg fresh frozen plasma (FFP group; n = 21) or HES (130/0.4) (HES group; n = 21) shortly after cardiopulmonary bypass termination. Activated partial thromboplastin time (aPTT) and international normalization ratio (INR) were measured. In addition, post‐operative transfusion requirements and blood loss until the end of the first post‐operative day were compared.Results: INR was significantly prolonged after HES infusion in comparison to the FFP group (P < 0.05). During the first 24 h after surgery, post‐operative blood loss, the use of allogenic blood/blood products and aPTT were similar in all children.Conclusions: Our study shows that the administration of a moderate dose of HES (130/0.4) in children undergoing cardiac surgery does not cause more bleeding or a higher transfusion requirement than a FFP infusion, and suggests that the administration of 10 ml/kg HES (130/0.4) is a safe alternative to plasma for intravascular volume replacement in this patient population.Keywords
This publication has 10 references indexed in Scilit:
- Albumin versus crystalloid prime solution for cardiopulmonary bypass in young childrenCritical Care Medicine, 2002
- Evaluation and Performance Characteristics of the STA-R Coagulation AnalyzerClinical Chemistry, 2002
- Effects of different plasma substitutes on blood coagulation: A comparative reviewCritical Care Medicine, 2001
- Voluven®, a Lower Substituted Novel Hydroxyethyl Starch (HES 130/0.4), Causes Fewer Effects on Coagulation in Major Orthopedic Surgery than HES 200/0.5Anesthesia & Analgesia, 2001
- The Influence of Intravascular Volume Therapy with a New Hydroxyethyl Starch Preparation (6% HES 130/0.4) on Coagulation in Patients Undergoing Major Abdominal Surgery: RetractedAnesthesia & Analgesia, 2001
- Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery?Anesthesia & Analgesia, 2000
- An international view of hydroxyethyl starchesIntensive Care Medicine, 1999
- Intraoperative Hetastarch Infusion Impairs Hemostasis After Cardiac OperationsThe Annals of Thoracic Surgery, 1997
- Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypassJournal of Cardiothoracic and Vascular Anesthesia, 1996
- RETRACTED: VOLUME REPLACEMENT WITH HYDROXYETHYL STARCH SOLUTION IN CHILDRENBritish Journal of Anaesthesia, 1993